The following information is based on a press release from Karo Pharma AB (Karo
Pharma) published on December 15, 2016 and may be subject to change.
The board of Karo Pharma has proposed that the Extraordinary General Meeting (EGM), scheduled for January 18, 2017, approves a rights issue for existing shareholders. The conditions are yet to be determined. The scheduled Ex-date is January 20, 2017. Provided that the EGM approves the rights issue, NASDAQ Derivatives Markets will carry out a re-calculation of options, forwards and futures in Karo Pharma (KAROB).
For further information please see the attached file.
Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=609077
The board of Karo Pharma has proposed that the Extraordinary General Meeting (EGM), scheduled for January 18, 2017, approves a rights issue for existing shareholders. The conditions are yet to be determined. The scheduled Ex-date is January 20, 2017. Provided that the EGM approves the rights issue, NASDAQ Derivatives Markets will carry out a re-calculation of options, forwards and futures in Karo Pharma (KAROB).
For further information please see the attached file.
Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=609077